AstraZeneca Pharma India (BOM:506820) EPS (Basic): ₹75.01 (TTM As of Mar. 2026)


BOM:506820 AstraZeneca Pharma India Ltd BOM:506820
85 GF Score
Price ₹8,382.65
GF Value ₹10,860.11
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India EPS (Basic)?

AstraZeneca Pharma India BOM:506820 -0.98% 85 EPS (Basic) is ₹75.01 as of Mar. 2026. GuruFocus rates BOM:506820 with a GF Score™ of 85/100 and a GF Value™ of ₹10,860.11 (Modestly Undervalued). The stock has 4 warning signs investors should review.

AstraZeneca Pharma India's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹17.95. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹75.01.

AstraZeneca Pharma India's EPS (Diluted) for the three months ended in Mar. 2026 was ₹17.95. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹75.01.

AstraZeneca Pharma India's EPS without NRI for the three months ended in Mar. 2026 was ₹18.28. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 76.61.

During the past 12 months, AstraZeneca Pharma India's average EPS without NRIGrowth Rate was 2.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 14.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 35.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, AstraZeneca Pharma India's highest 3-Year average EPS without NRI Growth Rate was 118.60% per year. The lowest was -35.80% per year. And the median was 18.80% per year.

AstraZeneca Pharma India  (BOM:506820) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

AstraZeneca Pharma India EPS (Basic) Related Terms

AstraZeneca Pharma India EPS (Basic) Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India EPS (Basic) Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.60 39.70 64.60 46.30 75.01

AstraZeneca Pharma India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.30 22.33 21.69 13.04 17.95
BOM:506820
85GF Score
AstraZeneca Pharma India Ltd BOM:506820
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

AstraZeneca Pharma India's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1875.2-0)/24.999
=75.01

AstraZeneca Pharma India's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(448.8-0)/25.003
=17.95

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹75.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹75.01 mean?
AstraZeneca Pharma India (BOM:506820) has a EPS (Basic) of ₹75.01 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on AstraZeneca Pharma India and its competitors.
Is AstraZeneca Pharma India's EPS (Basic) too high?
AstraZeneca Pharma India's current EPS (Basic) is ₹75.01. Overall, AstraZeneca Pharma India has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's EPS (Basic) compare to ZTS?
AstraZeneca Pharma India's EPS (Basic) of ₹75.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on AstraZeneca Pharma India and its competitors. AstraZeneca Pharma India's current EPS (Basic) is ₹75.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (BOM:506820) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,860.11, compared to a current price of ₹8,382.65 — trading 22.8% below its estimated fair value. The current EPS (Basic) is ₹75.01. AstraZeneca Pharma India's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For AstraZeneca Pharma India (BOM:506820), the current EPS (Basic) is ₹75.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca Pharma India (BOM:506820) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹8,382.65 is trading 22.8% below its estimated GF Value™ of ₹10,860.11. GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.

Key valuation signals for BOM:506820:

  • EPS (Basic): ₹75.01
  • GF Value™: ₹10,860.11 vs. price of ₹8,382.65 (22.8% below fair value)
  • GF Score™: 85/100 with 4 warning signs

No single metric tells the full story. See the BOM:506820 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Pharma India Business Description

Other Exchanges ASTRAZEN:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
85GF Score

Get the complete analysis for BOM:506820

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,382.65
Price
₹10,860.11
GF Value